Prime Medicine presents data from multiple studies showcasing LNP platform

Prime Medicine (PRME) presented data from multiple studies showcasing the potential of its proprietary, universal lipid nanoparticle, LNP, platform to precisely deliver Prime Editors to correct disease-causing mutations in the liver. The in vivo proof-of-concept data shared at the European Society of Gene and Cell Therapy, ESGCT, 31st Annual Congress demonstrated successful correction of disease-causing mutations in Wilson’s Disease in both mouse and non-human primate, NHP, models. Additionally, the Company highlighted the ability of its universal liver-targeted LNP platform to deliver Prime Editors to correct the underlying mutational cause of Glycogen Storage Disease Type 1b, GSD1b, in humanized mice and NHPs, reinforcing the potential for its modular LNP to support future programs in rare and non-rare liver indications.